Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Paris, 7 July 2026 – 5:45 pm HALF-YEAR STATEMENT ON RUBIS’ LIQUIDITY AGREEMENT WITH EXANE BNP PARIBAS Pursuant to the liquidity agreement that Rubis has entered into with Exane BNP Paribas,...
-
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The prediction markets sector is rapidly expanding in the digital finance and information field. These platforms...
-
Paris, 3 July 2026, 5:45 pm INFORMATION ON TOTAL NUMBER OF VOTING RIGHTS AND NUMBER OF SHARES PURSUANT TO ARTICLE L.233-8 II OF THE FRENCH COMMERCIAL CODE AND ARTICLE 223-16 OF THE GENERAL REGULATION...
-
eQ Plc Managers' Transactions3 July 2026 at 3:15 PM Person subject to the notification requirementName: Vanhanen & Sons OyPosition: Closely associated person(X) Legal person (1):Person...
-
eQ Plc Managers' Transactions30 June 2026 at 4:15 PM Person subject to the notification requirementName: Vanhanen & Sons OyPosition: Closely associated person(X) Legal person (1):Person...
-
EDISON, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), America’s leading innovator in designing, manufacturing, and providing...
-
THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS CALGARY, Alberta, June 30, 2026 (GLOBE...
-
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance...
-
Brooklyn, NY, June 25, 2026 (GLOBE NEWSWIRE) -- Silly Nice and stupidDOPE are returning to the Coney Island Boardwalk tonight for the second edition of the Coney Island Sunset Walk, a weekly 21+...
-
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin ...